<span item_type="fundamental" item_id="2ef7e34c094f94344cf8e7ba1d85d7d7" counter_id="ST/US/BIXT" env="prod"></span><span item_type="announcement" item_id="516462636410344577" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.02.</p><p></p><h3>Financial Metrics</h3><h4>Net Loss</h4><ul><li>Net loss for the three months ended March 31, 2025, was - $1,353,635, compared to - $560,522 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1445815/000164117225010822/form10-q.htm"></span></li></ul><h4>Operating Expenses</h4><ul><li>Total operating expenses for the three months ended March 31, 2025, were $515,142, compared to $779,229 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1445815/000164117225010822/form10-q.htm"></span></li></ul><h4>Research and Development</h4><ul><li>R&amp;D expenses for the three months ended March 31, 2025, were $349,500, compared to $27,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1445815/000164117225010822/form10-q.htm"></span></li></ul><h4>General and Administrative</h4><ul><li>General and administrative expenses for the three months ended March 31, 2025, were $165,642, compared to $752,229 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1445815/000164117225010822/form10-q.htm"></span></li></ul><h4>Cash Flow</h4><ul><li>Net cash used in operating activities was - $167,323 for the three months ended March 31, 2025, compared to - $109,567 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1445815/000164117225010822/form10-q.htm"></span></li><li>Net cash used in investing activities was - $15 for the three months ended March 31, 2025, compared to - $5,995 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1445815/000164117225010822/form10-q.htm"></span></li><li>Net cash provided by financing activities was $166,532 for the three months ended March 31, 2025, compared to $99,500 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1445815/000164117225010822/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><ul><li>The company plans to raise $3,700,000 to fund operations and continue product development over the next 15 months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1445815/000164117225010822/form10-q.htm"></span></li><li>Bioxytran, Inc. aims to develop and commercialize therapeutic molecules for stroke, with BXT-25 designed as an injectable anti-necrosis drug for ischemic stroke treatment.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1445815/000164117225010822/form10-q.htm"></span></li></ul><h4>Non-Core Business</h4><ul><li>The company intends to issue a Private Placement Offering under Regulation D for $4 million in the spring of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1445815/000164117225010822/form10-q.htm"></span></li></ul><h4>Priority</h4><ul><li>The company is focused on obtaining adequate funding to proceed with clinical trials and drug development, including a Phase 3 clinical trial for ProLectin-M, pending positive trial results.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1445815/000164117225010822/form10-q.htm"></span></li></ul>

Bioxytran, Inc. | 10-Q: FY2025 Q1 EPS: USD -0.02